Zuzana Sekeyová | Formulation Science | Best Researcher Award

Published on by Top Pharmaceutical

Mrs. Zuzana Sekeyová | Formulation Science | Best Researcher Award

Slovak Academy of Sciences | Slovakia

Mrs. Zuzana Sekeyová is a highly accomplished virologist and microbiologist with extensive expertise in the study, diagnosis, and prevention of rickettsial and intracellular pathogens. She obtained her Bachelor’s and Master’s degrees in Virology from Comenius University, Bratislava, and completed her Ph.D. at the Faculty of Natural Sciences, Comenius University, focusing on the biology of Rickettsiae and related organisms at the Institute of Virology, Slovak Academy of Sciences. She advanced her knowledge through postdoctoral training at the University of Maryland, Department of Microbiology and Immunology, Baltimore, USA, and through multiple visiting research fellowships supported by the Deutsche Akademische Austauschdienst (DAAD) at Justus Liebig Universität, Giessen, Germany, and the WHO Collaborative Center for Rickettsial Reference and Research, CNRS UPRESA 6020, Marseille, France. She further enhanced her global expertise as a visiting research fellow with the Japan Society for the Promotion of Science at Obihiro University of Agriculture & Veterinary Medicine and the National Institute of Infectious Diseases in Tokyo, Japan.Mrs. Sekeyová began her career as a scientific assistant and young scientist at the Institute of Virology, Slovak Academy of Sciences, progressing to senior research scientist and deputy head of the Department of Rickettsiology, where she currently oversees the Laboratory for Diagnosis and Prevention of Rickettsial and Chlamydial Infections. She serves as an expert verifier for the Slovak National Accreditation Service under the Good Laboratory Practice Compliance Program and is a key member of the National Reference Center for Surveillance and Laboratory Diagnostics of Rickettsiae. She is also an internationally recognized expert in synthetic biology, participating in the Open Ended Online Forum and the Ad Hoc Technical Expert Group under the United Nations Convention on Biological Diversity.Her research emphasizes the molecular biology, epidemiology, and diagnostics of rickettsial and related intracellular microorganisms, contributing to innovative detection methods and preventive strategies. Notable publications include Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles, Mucoadhesive and drug release of cholic acid based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies, and C-type natriuretic peptide induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells. Through decades of research, Mrs. Sekeyová has combined rigorous laboratory investigations with translational and global health applications, establishing herself as a leading authority in virology, rickettsial diseases, and synthetic biology, with a strong commitment to advancing international scientific collaboration and public health initiatives.

Profile: Orcid

Featured Publications

Špitalská, E., Sabaka, P., Komorníková, A., Minichová, L., Palkovičová, K., Fenollar, F., Škultéty, Ľ., Miková, E., Sekeyová, Z., & Fournier, P.-E. Abdominal manifestations of Q fever. International Journal of Infectious Diseases.

Danchenko, M., Benada, O., Škultéty, Ľ., & Sekeyová, Z. Culture Isolate of Rickettsia felis from a Tick. International Journal of Environmental Research and Public Health.

Sekeyová, Z. Case studies of rickettsiosis, anaplasmosis and Q fever in Slovak population from 2011 to 2020. Biologia.

Sekeyová, Z. Detection of Rickettsia raoultii in Dermacentor reticulatus and Haemaphysalis inermis ticks in Slovakia. Biologia.

Sekeyová, Z. Hymenopteran Parasitoids of Hard Ticks in Western Africa and the Russian Far East. Microorganisms.

Liangxing Tu | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Liangxing Tu | Drug Delivery Systems | Best Researcher Award

Jiangxi University of Chinese Medicine | China

Prof. Dr. Liangxing Tu is a distinguished pharmaceutical scientist recognized for his extensive contributions to drug delivery systems and biopharmaceutics. He earned his Ph.D. in Pharmaceutics from the Shanghai University of Traditional Chinese Medicine, where he developed a strong foundation in advanced pharmaceutical formulations and nanotechnology-based therapeutics. After completing his doctoral studies, he began his professional journey at FosunPharma in Shanghai, where he contributed to pharmaceutical innovation and product development. He later joined the Jiangxi University of Traditional Chinese Medicine, where he currently serves as the Director of the Division of Innovative Pharmaceutical Sciences, leading cutting-edge research in formulation science and nanomedicine.Dr. Tu’s research focuses on developing advanced drug delivery systems, including nanocrystals, polymeric micelles, and vesicular systems, to enhance the oral bioavailability and therapeutic efficacy of poorly soluble drugs. His work also extends to exploring biopharmaceutics mechanisms to improve the in vivo performance of active pharmaceutical ingredients. His innovative approaches have positioned him at the forefront of translational pharmaceutics, bridging the gap between laboratory research and clinical applications.He is an active member of the Chinese Pharmaceutical Association and contributes his expertise as a member of the Elsevier Advisory Panel. Additionally, he serves on the Editorial Board of Chinese Chemical Letters (ISSN: 1001-8417), reflecting his strong academic presence and influence in the pharmaceutical sciences community. Dr. Tu has been awarded multiple research grants, including projects funded by the National Natural Science Foundation of China and other governmental bodies, underscoring the national and international recognition of his research excellence.Dr. Tu has published around 30 peer-reviewed papers in top-tier journals such as Chinese Chemical Letters, Drug Delivery, and the International Journal of Pharmaceutics. His representative publications include “Vesicular Drug Delivery Systems for Oral Absorption Enhancement,” “Multi-functional Chitosan Copolymer Modified Nanocrystals as Oral Andrographolide Delivery Systems for Enhanced Bioavailability and Anti-inflammatory Efficacy,” “Fabrication of Ultra-Small Nanocrystals by Formation of Hydrogen Bonds: In Vitro and In Vivo Evaluation,” “Multi-functional Chitosan Polymeric Micelles as Oral Paclitaxel Delivery Systems for Enhanced Bioavailability and Anti-Tumor Efficacy,” and “Study on the Preparation of Stabilizer-Free Silymarin Nanocrystals and Its Oral Absorption Mechanisms.”

Profile: Orcid

Featured Publications

Wang, J., Sun, Y., Meng, L., Feng, J., Cheng, M., & Tu, L. Intestinal transporters and oral absorption enhancing strategies based on these transporters. Chinese Chemical Letters.

Li, Z., Yao, L., Liu, Z., Wang, L., Ruan, H., Shen, Y., Zhang, P., Li, K., Wang, H., Fan, L., et al. Andrographolide Sulfonates and Xiyanping: A Review of Chemical Composition, Pharmacological Activities, Clinical Applications, and Adverse Reactions. Pharmaceuticals.

Tu, L., Wang, J., Sun, Y., & Wan, Y. Fabrication of Luteolin Nanoemulsion by Box-Behnken Design to Enhance its Oral Absorption Via Lymphatic Transport. AAPS PharmSciTech.

Zou, L., Cheng, M., Hu, K., Feng, J., & Tu, L. Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters.

He, Y., Cheng, M., Yang, R., Li, H., Lu, Z., Jin, Y., Feng, J., & Tu, L. Research Progress on the Mechanism of Nanoparticles Crossing the Intestinal Epithelial Cell Membrane. Pharmaceutics.

Liu, W., Cheng, M., Yuan, F., He, J., Feng, Y., Jin, Y., Yang, S., Feng, J., & Tu, L. Enhancing oral bioavailability of andrographolide via sodium dodecyl sulfate and D-α-Tocopherol polyethylene glycol 1000 succinate copolymer modified nanocrystals. Journal of Drug Delivery Science and Technology.

Liu, W., Cheng, M., Lu, Z., Li, H., Feng, Y., Jin, Y., Yang, S., Feng, J., & Tu, L. Multi-functional chitosan copolymer modified nanocrystals as oral andrographolide delivery systems for enhanced bioavailability and anti-inflammatory efficacy. Drug Delivery.

Rahul K. Reddy – Pharmacology – Excellence in Research

Published on by Top Pharmaceutical

Rahul K. Reddy - Pharmacology - Excellence in Research

Lautoka Hospital - Fiji

Introduction

Rahul K. Reddy is an accomplished researcher and medical professional specializing in urology, surgery, and trauma care. With a focus on advancing medical understanding and clinical outcomes in challenging cases, Dr. Reddy has contributed significantly to the fields of laparoscopic surgery, burn care, and acute surgical conditions. His work is characterized by its depth of clinical insight and dedication to improving patient outcomes in diverse healthcare settings, particularly in Fiji.

Laparoscopic Surgery in Urology

Dr. Reddy's pioneering work in the laparoscopic excision of seminal vesicle cystadenoma underscores his expertise in minimally invasive surgical techniques. Published in Urology Case Reports (2019), this study has provided valuable insights into rare urological conditions, offering innovative approaches to their management.

Burn Injury Characteristics and Outcomes

In collaboration with a multidisciplinary team, Dr. Reddy conducted an in-depth analysis of burn injury patterns and treatment outcomes at Lautoka Hospital. His findings, featured in Burns Open (2024), have contributed to the optimization of burn care protocols in resource-limited settings, enhancing recovery rates and patient care quality.

Acute Appendicitis Management

Through an observational retrospective study on acute appendicitis at Lautoka Aspen Hospital, Dr. Reddy explored the clinical characteristics and outcomes over a one-year period (2022–2023). Published in World Journal of Surgical Research (2024), this research offers evidence-based recommendations for improving appendicitis management in Pacific Island healthcare systems.

Rare Tumors and Pathologies

Dr. Reddy has also delved into the study of rare pathologies, such as primary epithelioid hemangioendothelioma of the kidney pelvis. His case report, published in the American Journal of Surgery and Clinical Case Reports (2020), adds to the limited literature on this rare tumor type, emphasizing the importance of early diagnosis and tailored surgical interventions.

Trauma and Emergency Medicine

With a holistic approach to trauma care, Dr. Reddy's research addresses the critical needs of patients in emergency settings. His work highlights the significance of multidisciplinary collaboration and protocol-driven management in achieving favorable outcomes for complex trauma cases.

Conclusion

Rahul K. Reddy’s extensive research portfolio reflects his unwavering commitment to advancing medical science and improving patient care. By addressing diverse challenges in urology, surgery, and trauma care, Dr. Reddy continues to contribute to the development of innovative treatments and clinical best practices, with a lasting impact on global and regional healthcare.

NOTABLE PUBLICATION

Laparoscopic excision of seminal vesicle cystadenoma 2019 (4)

Burns injury characteristics and outcomes at lautoka hospital, fiji 2024

Characteristics and Outcomes of Acute Appendicitis in Lautoka Aspen Hospital, Fiji: An Observational Retrospective Study (09/22–09/23) 2024

Primary Epithelioid Hemangioendothelioma of the Kidney Pelvis 2020